London · Delayed Price · Currency is GBP · Price in GBX Anpario Earnings Call Transcripts
Fiscal Year 2025
-
Revenue rose 34% year-over-year, with strong growth across most regions and a significant contribution from the Bio-Vet acquisition. Gross margin and profitability improved, cash reserves increased, and the outlook remains positive despite ongoing trade and credit risks.
Fiscal Year 2024
-
Revenue and profit rebounded strongly with 23% top-line growth and a 57% rise in adjusted EBITDA, driven by broad-based segment recovery and the Bio-Vet acquisition. Gross margins improved, cash remains strong, and the outlook is positive with continued focus on growth and resilience.
-
Gross margin recovery, strong cash generation, and global diversification underpin optimism for high single-digit sales growth. Ongoing product innovation, M&A, and operational leverage are expected to drive future profit expansion despite regulatory and logistics risks.